What happened with UG today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
United-Guardian earns the largest share of its sales from pharmaceuticals. Its main drug, Renacidin, and its other drug, Clorpactin, are sold primarily to three national drug wholesalers, which buy them for resale to hospitals, pharmacies and other healthcare buyers. Renacidin is made by an outside contract manufacturer, so the company depends on that supplier to fill orders; its other marketed products are made at its own New York facility.
The company also supplies cosmetic and personal-care manufacturers with ingredients such as Lubrajel, a water-based moisturizing and lubricating gel. Distributors buy these ingredients outright and handle most marketing and resale. Ashland Specialty Ingredients is the largest distributor and accounts for a substantial share of company sales, making its orders important to the business. United-Guardian continues working with Ashland while negotiating a replacement for their expired distribution agreement.
Medical lubricants provide another source of revenue. United-Guardian sells water-based gels directly to medical-product manufacturers and their contract manufacturers for use in catheters and other devices. The makers of the finished products are responsible for obtaining their regulatory approvals; United-Guardian must manufacture its lubricants under current good manufacturing practices, and its facility is subject to FDA oversight.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
United-Guardian’s results hinge not primarily on the consumer beauty companies shown here, but also on reliable contract manufacturing and wholesaler demand for Renacidin, its largest pharmaceutical product.
United-Guardian depends on Ashland’s purchases of its cosmetic ingredients for resale to beauty and personal-care manufacturers: Ashland also sells its own personal-care ingredients to formulators, and its distribution business accounted for 22% of United-Guardian’s 2025 sales. Watch Ashland’s inventory and Asian demand for United-Guardian’s products—Ashland reported overstocking and weaker demand there, which drove lower purchases and most of United-Guardian’s 2025 cosmetic-ingredient sales decline.
Ashland Inc. earningsASH
Ashland’s report will show whether Asian demand and inventory are changing its sales of personal-care ingredients to formulators—and, in turn, its purchases of cosmetic ingredients from United-Guardian.
Read Ashland’s Asian demand alongside its inventory. If demand improves and inventory falls, Ashland has more reason to replenish, which could ease pressure on United-Guardian’s cosmetic-ingredient sales through its largest distributor. If demand stays weak and inventory remains high, Ashland may keep limiting purchases, leaving that revenue channel under pressure. Ashland’s sales and inventory are not the same as its orders from United-Guardian; United-Guardian’s own subsequent sales will confirm the effect.
